LungLifeAI Logo

Investors

AIM Rule 26 Information

This area of the web site contains all information which is required to be disclosed in accordance with Rule 26 of the AIM Rules.

Description of the Business

Names of the directors, biographical details and responsibilities

Corporate governance

Country of incorporation / operation

Shareholder Information

  • Other Exchanges and Trading Platforms
  • Shares in Issue
  • Significant Shareholdings
  • Director Shareholdings
  • Shares Not in Public Hands
  • Restrictions in Transfer of AIM Securities
  • UK City Code on Takeovers and Mergers

Advisors

Announcements and Notifications

see News

Q&A with LungLife AI's CEO, Paul Pagano

Half-year Report For The Six Months Ended 30 June 2023

Featured News

September 9, 2022

Notice of Results (09.09.22)

LungLife AI, Inc. (the “Company” or “LungLife”)   Notice of Results Investor Presentation   LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, will announce its interim results for the six months ended 30 June 2022 on Monday 26 September 2022.   Investor presentation Paul Pagano, Chief Executive Officer, and David […]
• Read More
September 2, 2022

New York State approves LungLB® for commercial testing

LungLife AI, Inc. (the “Company” or “LungLife”)   New York State approves LungLB® for commercial testing   LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces that the New York State Department of Health (“NYSDOH”) has awarded LungLife a Clinical Laboratory Evaluation Program (“CLEP”) permit following their recent on-site audit, during […]
• Read More
LungLifeAI Logo
LungLife AI licensure/accreditation information posted here.
© 2023 LungLIfe AI, Inc.
All rights reserved. LiquidBiopsy is a trademark of LungLife AI, Inc.
crosschevron-down